0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Integrin alpha V beta 3

Integrin alpha V beta 3

Integrin alpha V beta 3 Molecule Information

Name:Integrin alpha-V/beta-3
Target Synonym:Integrin alphaVbeta3
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:11
Lastest Research Phase:Phase 3 Clinical

Integrin alpha V beta 3 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
IT3-H52E3 Human Human Integrin alpha V beta 3 (ITGAV&ITGB3) Heterodimer Protein, His Tag&Tag Free
IT3-H52E3-structure
IT3-H52E3-sds
IT3-H52E3-elisa_1

Integrin alpha V beta 3 Part of Bioactivity data

IT3-H52E3-MALS-HPLC
Human ITGAV&ITGB3 Heterodimer Protein, His Tag&Tag FreeHuman ITGAV&ITGB3 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT3-H52E3) ELISA bioactivity

Immobilized Human Fibronectin at 2 μg/mL (100 μL/well) can bind Human ITGAV&ITGB3 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT3-H52E3) with a linear range of 0.01-0.313 μg/mL (QC tested).

Integrin alpha V beta 3 Molecule Synonym Name

Integrin alpha V beta 3,ITGAV&ITGB3,ITGAV&B3

Integrin alpha V beta 3 Molecule Background

Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Also, Integrin alpha-V/beta-3 acts as a receptor for herpes virus 8/HHV-8, coxsackievirus A9, Hantaan virus, cytomegalovirus/HHV-5, human metapneumovirus, human parechovirus 1 and west nile virus. Furthermore, in case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.

Integrin alpha V beta 3 References

Integrin alpha V beta 3 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Risuteganib ALG-1001 Phase 2 Clinical Allegro Ophthalmics Retinal Diseases; Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration Details
68Ga-NOTA-BBN-RGD 68Ga-NOTA-BBN-RGD Phase 1 Clinical Peking Union Medical College Hospital Breast Neoplasms; Prostatic Neoplasms Details
68Ga-NOTA-3PTATE-RGD 68Ga-NOTA-3PTATE-RGD; 68Ga-NOTA-3P-TATE-RGD Phase 1 Clinical Peking Union Medical College Hospital Lung Neoplasms Details
SF-0166 SF-0166 Phase 2 Clinical Scifluor Life Sciences Diabetic macular oedema; Macular Degeneration Details
派格安替安吉肽 Phase 1 Clinical Nanjing Anji Biological Technology Co Ltd, Jiangsu Aotexin Biomedical Technology Co Ltd, China Pharmaceutical University Rheumatic Diseases Details
Peptide-based PET radiotracer (Stanford University) Phase 2 Clinical Stanford University Neoplasms Details
Antiangiotide HM-3; IIM-3 Phase 1 Clinical Neimenggu Tianqi Mnegyao Group Co Ltd, China Pharmaceutical University Solid tumours; Liver Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung Details
IDL-2965 IDL-2965 Phase 2 Clinical Indalo Therapeutics Non-alcoholic Fatty Liver Disease; Idiopathic Pulmonary Fibrosis Details
Alfatide[18F] Phase 1 Clinical Taizhou Kairui Pharmaceutical Technology Co Ltd, Jiangsu Smk Pharmaceutical Co Ltd Neoplasms Details
Abituzumab DI-17E6; EMD-525797 Phase 2 Clinical Merck Serono Bone metastases; Solid tumours; Scleroderma, Systemic; Ovarian Diseases; Prostatic Neoplasms; Colorectal Neoplasms Details
99mTc-3PRGD2 99mTc-3PRGD2 Phase 3 Clinical Peking University Contrast agents; Lymphatic Metastasis; Lung Neoplasms Details
AS-101 WAX-120337; IVAX-Q-101; IVX-Q-101; CB-06-02; AS-101; PRX-001; PRX-0002/AS101; PRX-0001/AS101 Phase 2 Clinical Biomas Warts; Myelodysplastic Syndromes; Psoriasis; Leukemia, Myeloid, Acute; Thrombocytopenia; Macular Degeneration; Condylomata Acuminata; Dermatitis, Atopic Details
[68Ga]-FF58 Phase 1 Clinical Glioblastoma; Brain Neoplasms Details

This web search service is supported by Google Inc.

totop